Clarient Diagnostic Services, a GE Healthcare company, has entered into an agreement to license genomic biomarker for lung cancer from Insight Genetics.
AS per the agreement, Clarient intends to develop and assess the performance characteristics of a quantitative PCR-based test to identify patients who have ALK-positive lung cancers.
Clarient chief medical officer Kenneth Bloom said the National Comprehensive Cancer Network guidelines now suggest ALK testing as a standard measure for all non-small cell lung cancer patients due to the development of therapies targeting ALK inhibition.
"Our agreement with Insight Genetics is another example of our mission of translating biomarker discovery to aid the development of new therapeutics and to assist physicians in determining the eligibility of their patients to receive the most appropriate therapy," Bloom added.
Insight Genetics chairman and CEO Eric Dahlhauser said the company and Clarient share a dedication to enhance personalized cancer care.
"We’re pleased to work with Clarient, a leader in cancer diagnostics with a strong commitment to developing tests that address targeted therapies, toward advancing this common goal," Dahlhauser added.